|
| Press Releases |
|
 |
|
| Saturday, August 31, 2013 |
|
|
NANOBIOTIX: Half Year Results for the Period Ended 30 June 2013 |
| NANOBIOTIX (the "Company") (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). more info >> |
|
| Thursday, July 4, 2013 |
|
|
Nanobiotix Announces EUR 2.8 Million Grant from bpifrance to Accelerate Development of NBTXR3 in a Third New Indication |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. more info >> |
|
| Wednesday, June 26, 2013 |
|
|
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. more info >> |
|
| Thursday, June 13, 2013 |
|
|
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO) announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM, to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. more info >> |
|
| Monday, June 3, 2013 |
|
|
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
エーザイとMerck & Co., Inc、進行腎細胞がん（RCC）患者様を対象とした一次治療としての併用療法を評価する臨床第III相「LITESPARK-012」試験の状況について
Apr 22, 2026 10:40: JST
|
|
|
ソニー・ホンダモビリティの今後の事業の方向性について
Apr 22, 2026 10:10: JST
|
|
|
Seven HKTDC Lifestyle and Licensing mega events to open next week
Apr 22, 2026 09:47 HKT/SGT
|
|
|
A new system to track material design processes
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology 推出 Agentic AI 儲存產品組合，以消除 KV 快取瓶頸
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology 推出 Agentic AI 存储产品组合，旨在消除 KV 缓存瓶颈
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Graid Technology Launches Agentic AI Storage Portfolio to Eliminate KV Cache Bottlenecks
Apr 22, 2026 03:00 HKT/SGT
|
|
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 22, 2026 01:04: JST
|
|
|
Genius Foundation's GENIUS Token Surges Following TGE, Briefly Tops $800 Million FDV
Apr 21, 2026 22:46 HKT/SGT
|
|
|
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST
|
|
|
New Report Reveals Widespread Misunderstanding of Consumer Messaging App Security Across Government and Critical Infrastructure
Apr 21, 2026 19:00 HKT/SGT
|
|
|
Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST
|
|
|
Global Turbine Asia Advances Aerospace Growth, Capabilities and Talent Development Through Strategic Partnerships
Apr 21, 2026 17:39 HKT/SGT
|
|
|
GMG's Graphene Engine Oil Additive G(R) LUBRICANT: Patent Granted in USA; Allowed in China
Apr 21, 2026 17:07 HKT/SGT
|
|
|
トヨタ、幹部職人事について
Apr 21, 2026 16:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
